Skeletal Muscle Quality Screening in Individuals with Obesity

Abstract

Obesity is a pervasive global health issue, and its association with skeletal muscle dysfunction has significant implications for morbidity and mortality. Recent scientific advances underscore the importance of assessing not only muscle mass but also muscle quality, which incorporates factors such as muscle composition, strength, and metabolic function. This review explores the clinical relevance, mechanisms, screening modalities, and management strategies for skeletal muscle quality in individuals with obesity, synthesizing current guidelines and emerging research to inform evidence-based practice for healthcare professionals.

Introduction

Obesity is characterized by excessive adipose tissue accumulation, but it also profoundly affects skeletal muscle composition and function. The paradigm has shifted from focusing solely on muscle mass to appreciating the multifaceted concept of muscle quality, encompassing aspects such as fat infiltration (myosteatosis), fibrosis, mitochondrial dysfunction, and functional capacity. Screening for compromised muscle quality in obese patients is crucial, as it portends adverse metabolic, functional, and cardiovascular outcomes. This article provides a comprehensive overview of skeletal muscle quality screening in the context of obesity, integrating evidence-based insights for clinical implementation.

Epidemiology / Disease Burden

Globally, over 650 million adults are classified as obese, with prevalence rates continuing to rise. Epidemiological studies reveal that up to 50% of individuals with obesity exhibit reduced muscle quality manifested as diminished strength, increased intramuscular adiposity, and impaired metabolism. This phenotype, often termed "sarcopenic obesity" is associated with increased risk for type 2 diabetes, cardiovascular disease, mobility limitations, and mortality. The burden of poor muscle quality is especially pronounced among older adults and those with comorbidities, compounding healthcare costs and straining clinical resources.

Pathophysiology

The pathophysiology of impaired muscle quality in obesity is multifactorial. Ectopic lipid deposition within myocytes (myosteatosis) disrupts insulin signaling and mitochondrial function, fostering insulin resistance and chronic inflammation. Adipokines such as leptin and adiponectin, along with pro-inflammatory cytokines (e.g., TNF-α, IL-6), further impair muscle protein synthesis and promote fibrosis. Reduced physical activity, oxidative stress, and hormonal dysregulation exacerbate these changes, resulting in decreased muscle force generation, endurance, and metabolic flexibility. Importantly, these alterations may occur even in the presence of preserved or increased muscle mass, underscoring the necessity of quality-based assessment.

Risk Factors

Key risk factors for impaired muscle quality in obesity include advancing age, physical inactivity, chronic low-grade inflammation, insulin resistance, and specific genetic predispositions. Comorbidities such as type 2 diabetes, metabolic syndrome, and chronic kidney disease amplify the risk. Dietary patterns rich in saturated fats and low in protein, along with vitamin D deficiency and persistent hyperglycemia, further contribute to muscle quality deterioration. Certain medications (e.g., glucocorticoids, statins) and endocrine disorders also play contributory roles.

Clinical Features

Clinically, compromised muscle quality in individuals with obesity may manifest as reduced muscle strength and endurance, impaired mobility, increased fatigability, and difficulty performing activities of daily living. Patients may report frequent falls, slower gait speed, and decreased exercise tolerance. Objective findings often include decreased handgrip strength, reduced chair rise performance, and lower scores on composite physical function tests such as the Short Physical Performance Battery (SPPB). Importantly, these functional deficits may precede overt loss of muscle mass, highlighting the need for early detection through quality-focused screening.

Diagnosis

Screening for muscle quality in obesity requires a multimodal approach. Handgrip dynamometry and isokinetic strength testing provide quantitative measures of muscle function. Imaging modalities including dual-energy X-ray absorptiometry (DXA) for muscle mass, computed tomography (CT), and magnetic resonance imaging (MRI) enable assessment of intramuscular fat infiltration and muscle architecture. Emerging biomarkers such as circulating creatinine, myostatin, and inflammatory cytokines offer adjunctive diagnostic value. Functional assessments (e.g., gait speed, SPPB, timed up-and-go) are essential for risk stratification. Consensus guidelines recommend integrating these tools to capture the full spectrum of muscle quality impairment.

Treatment & Management

Management strategies for improving muscle quality in obesity are multifaceted, targeting both lifestyle and pharmacological interventions. Resistance and aerobic exercise regimens are foundational, demonstrating efficacy in enhancing muscle strength, reducing myosteatosis, and improving metabolic function. Nutritional optimization, with emphasis on adequate protein intake (1.2–1.5 g/kg/day), vitamin D repletion, and anti-inflammatory dietary patterns, supports muscle anabolism and function. Pharmacotherapies, including selective androgen receptor modulators and myostatin inhibitors, are under investigation but not yet widely adopted. Bariatric surgery may improve muscle quality indirectly through weight reduction, though careful postoperative monitoring is essential to prevent iatrogenic muscle loss. Multidisciplinary care including physical therapists, dietitians, and endocrinologists is paramount for comprehensive management.

Recent Advances / Emerging Therapies

Recent research has unveiled novel insights into the molecular regulation of muscle quality, identifying pathways such as AMPK, mTOR, and SIRT1 as potential therapeutic targets. Non-invasive imaging techniques, including ultrasound elastography and advanced MRI spectroscopy, allow for detailed characterization of muscle composition. Pharmacological agents targeting myostatin and activin signaling are in clinical trials, offering promise for future interventions. Digital health tools, such as wearable sensors and tele-rehabilitation platforms, facilitate remote monitoring and personalized exercise prescription. Ongoing studies are elucidating the long-term impact of combined lifestyle and pharmacological approaches on muscle quality and clinical outcomes.

Guideline Recommendations

Leading societies, including the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Working Group on Sarcopenia in Older People (EWGSOP), emphasize routine screening for muscle quality in individuals with obesity particularly those with metabolic comorbidities or functional decline. Guidelines advocate for a combination of functional testing, imaging, and biochemical markers to inform diagnosis and guide therapy. Early identification and intervention are strongly recommended to reduce morbidity, preserve independence, and optimize long-term outcomes. Interdisciplinary collaboration and individualized care plans are highlighted as best practices.

Conclusion

Skeletal muscle quality screening represents a critical component of comprehensive obesity management. By moving beyond traditional measures of muscle mass to embrace multifaceted quality assessments, clinicians can identify at-risk patients, tailor interventions, and mitigate adverse outcomes. Ongoing research and guideline development will continue to refine screening protocols and therapeutic strategies, fostering improved patient care and population health.